Arch Biopartners Inc ( ACHFF ):
* ARCH STRENGTHENS ITS POSITION AS A LEADING KIDNEY
THERAPEUTICS
COMPANY WITH THE ACQUISITION OF A BREAKTHROUGH PLATFORM TO
DEVELOP NEW DRUGS TARGETING CHRONIC KIDNEY DISEASE (CKD)
Source text:
Further company coverage: